Neurologic, MR imaging, and MR spectroscopic findings in eosinophilia myalgia syndrome

American Journal of Neuroradiology

Volumn 19, Issue 9, 1998, Pages 1687-1694

  Haseler, Luke J ^a,b   Sibbitt Jr , Wilmer L ^a,d   Sibbitt, Randy R ^c   Hart, Blaine L ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c St Peter's Hospital Helena   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EOSINOPHILIA MYALGIA SYNDROME; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AGED; BRAIN; BRAIN DISEASES; DISABLED PERSONS; EOSINOPHILIA-MYALGIA SYNDROME; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; NEUROLOGIC EXAMINATION; REFERENCE VALUES;

EID: 0032471430     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Centers for Disease Control. Eosinophilia-myalgia syndrome-New Mexico. MMWR Morb Mortal Wkly Rep 1989;38:765-767
2. Centers for Disease Control. Eosinophilia-myalgia syndrome and L-tryptophan-containing products in New Mexico, Minnesota, Oregon, and New York. MMWR Morb Mortal Wkly Rep 1989;38: 785-788
3. Hertzman PA, Clauw DJ, Kaufman LD, et al. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 1995;122:851-855
4. Kaufman, LD, Finn AF, Seidman RJ, et al. Eosinophilic neuritis, perimyositis, and vasculitis associated with ingestion of L-tryptophan. J Rheumatol 1990;17:795-800
5. Kaufman LD, Seidman RJ, Gruber BL. L-Tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis: a clinicopathological and laboratory study of 25 patients. Medicine (Baltimore) 1990;69:187-199
6. Seidman RJ, Kaufman LD, Sokoloff L, Miller F, Iliya A, Peress NS. The neuromuscular pathology of the eosinophilia-myalgia syndrome. J Neuropathol Exp Neurol 1991;50:49-62
7. Selwa JF, Feldman EL, Blaivas M. Mononeuropathy multiplex in tryptophan-associated eosinophilia-myalgia syndrome. Neurology 1990;40:1632-1633
8. Verity AM, Blupitt KJ, Paulus ME. Neuromuscular manifestations of L-tryptophan-associated eosinophilia-myalgia syndrome: a histomorphometric analysis of 14 patients. Hum Pathol 1991;22:3-11
9. Varga J, Heiman-Patterson TD, Emery DL, et al. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum 1990;19:313-328
10. Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: clinical features in 20 patients and aspects of pathophyslology. Ann Intent Med 1990;113:124-134
11. Hertzman PA, Falk H, Kilbourne EM, Page S, Shulman LE. The eosinophilia-myalgia syndrome: the Los Alamos conference. J Rheumatol 1991;8:867-873
12. Culpepper RC, Williams RG, Mease PJ, Koepsell TD, Kobayashi JM. Natural history of the eosinophilia-myalgia syndrome. Ann Intern Med 1991;155:437-442
13. Kaufman LD. Chronicity of the eosinophilia-myalgia syndrome: a reassessment after three years. Arthritis Rheum 1994;37:84-87
14. Kaufman LD, Kaufman MA, Krupp LB. Movement disorders in the eosinophilia-myalgia syndrome: tremor, myoclonus, and myokymia. J Rheumatol 1995;22:157-160
15. Lynn J, Rammohan KW, Bornstein RA, Kissel JT. Central nervous system involvement in the eosinophilia-myalgia syndrome. Arch Neurol 1992;49:1082-1085
16. Epstein SA, Krahn L, Clauw DJ, Gomes AP, Weigert S, Goldberg RL. Psychiatric aspects of the eosinophilia-myalgia syndrome. Psychosomatics 1995;36:22-25
17. Mierendorf SM, Bloch DA, McGuire JL, Lambert RE. Early and late neuropsychiatric manifestations of eosinophilia-myalgia syndrome. Arthritis Rheum 1992;35(Suppl):S66
18. Krupp LB, Masur DM, Kaufman LD. Neurocognitive dysfunction in the eosinophilia-myalgia syndrome. Neurology 1993;43:931-936
19. World Health Organization. International Classification of Impairments, Disabilities, and Handicaps. Geneva: WHO; 1980
20. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987;508:333-348
21. Salvan AM, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy: comparison between sequences using short and long echo times. Invest Radiol 1997;32:485-495
22. Sibbitt WL Jr, Haseler LH, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NA. Analysis of cerebral structural changes in systemic lupus erythematosus by proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 1994;45:923-928
23. Sibbitt WL Jr, Haseler LJ, Griffey RR, Friedman SD, Brooks WM. Neurometabolism of active neuropsychiatric lupus determined by proton MR spectroscopy. AJNR Am J Neuroradiol 1997;48:1271-1277
24. Brooks WM, Sabet A, Sibbitt WL Jr, et al. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol 1997;24:2323-2329
25. Marshall I, Wardlaw J, Cannon J, Slattery J, Sellar RJ. Reproducibility of metabolite peak areas in 1H MRS of brain. Magn Reson Imaging 1996;14:281-292
26. Kreis R, Farrow N, Ross BD. Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy: analysis of changes in cerebral glutamine, choline and myo-inositol. NMR Biomed 1991;4:109-116
27. Silver RM. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1993; 5:802-808
28. Hill RH Jr, Caudill SP, Philen RM, et al. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome. Arch Environ Contain Toxicol 1993;25:134-142
29. Kaufman LD. The eosinophilia-myalgia syndrome: current concepts and future directions. Clin Exp Rheumatol 1992;10:87-91
30. Sullivan EA, Kamb ML, Jones JL, et al. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Arch Intern Med 1996;156:973-979
31. Dicker, RM, James, N, Cunha BA. The eosinophilia-myalgia syndrome with neuritis associated with L-tryptophan use. Ann Intern Med 1990;126:957-958
32. Varga J, Uitto J, Jimenez SA. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med 1992;116:140-147
33. Hartlage LC, Horton AM. Neuropsychological and emotional sequelae of eosinophilia-myalgia syndrome. Int J Neurosci 1993;72: 251-255
34. Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol 1990;11: 431-439
35. Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992;19:732-741
36. Brenner RE, Munro PMG, Williams SCR, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993;29:737-745
37. Haseler LJ, Sibbitt WL Jr, Mojtahedzadeh HN, Reddy S, Agarwal VP, McCarthy MP. Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy. AJNR Am J Neuroradiol 1998;9:
38. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn Reson Med 1989;9:126-131
39. Luyten PR, den Hollander JA. Observation of metabolites in the human brain by MR spectroscopy. Radiology 1986;161:795-798
40. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glulamate: region levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984;43:1136-1142
41. Brenneman DE, Page SW, Schultzberg M, et al. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms. J Pharmacol Exp Ther 1993;266:1029-1035
42. Crockard HA, Gadian DG, Frackowiak RS, et al. Acute cerebral ischemia: concurrent changes in cerebral blood flow, energy metabolism, pH, and lactate measured with hydrogen clearance and 31P and 1H nuclear magnetic resonance spectroscopy, II: changes during ischemia. J Cereb Blood Flow Metab 1987;7:394-402
43. Mathews VP, Barker PB, Blackband SJ, Chatham JC, Bryan RN. Cerebral metabolites in patients with acute and subacute strokes: concentrations determined by quantitative proton MR spectroscopy. AJR Am J Roenigenol 1995;165:633-638
44. Davis CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58
45. Sibbitt WL, Jr, Sibbitt RR. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 1993;19; 851-868